1-7 of 7
Daniel L. Hertz
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy

Daniel L. Hertz, Kelley M. Kidwell, Kiran Vangipuram, Feng Li, Manjunath P. Pai, Monika Burness, Jennifer J. Griggs, Anne F. Schott, Catherine Van Poznak, Daniel F. Hayes, Ellen M. Lavoie Smith, N. Lynn Henry
Journal: Clinical Cancer Research
Clin Cancer Res (2018) 24 (15): 3602–3610.
https://doi.org/10.1158/1078-0432.CCR-18-0656
Published: 31 July 2018
View articletitled, Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy
Open the PDF for Paclitaxel Plasma Concentration after the First Infusion Predicts Treatment-Limiting Peripheral Neuropathy in another window
Includes: Supplementary data
Journal Articles

Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer

M. Eileen Dolan, Omar El Charif, Heather E. Wheeler, Eric R. Gamazon, Shirin Ardeshir-Rouhani-Fard, Patrick Monahan, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Clair J. Beard, Chunkit Fung, Jeri Kim, Sophie D. Fossa, Daniel L Hertz, Taisei Mushiroda, Michiaki Kubo, Lawrence H. Einhorn, Nancy J. Cox, Lois B. Travis
Journal: Clinical Cancer Research
Clin Cancer Res (2017) 23 (19): 5757–5768.
https://doi.org/10.1158/1078-0432.CCR-16-3224
Published: 01 October 2017
View articletitled, Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer
Open the PDF for Clinical and Genome-Wide Analysis of Cisplatin-Induced Peripheral Neuropathy in Survivors of Adult-Onset Cancer in another window
Includes: Supplementary data
Journal Articles

Individualized Tamoxifen Dose Escalation—Response

Daniel L. Hertz, James M. Rae
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (24): 6301.
https://doi.org/10.1158/1078-0432.CCR-16-2351
Published: 15 December 2016
View articletitled, Individualized Tamoxifen Dose Escalation—Response
Open the PDF for Individualized Tamoxifen Dose Escalation—Response in another window
Journal Articles

Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy

Daniel L. Hertz, Kouros Owzar, Sherrie Lessans, Claudia Wing, Chen Jiang, William Kevin Kelly, Jai Patel, Susan Halabi, Yoichi Furukawa, Heather E. Wheeler, Alexander B. Sibley, Cameron Lassiter, Lois Weisman, Dorothy Watson, Stefanie D. Krens, Flora Mulkey, Cynthia L. Renn, Eric J. Small, Phillip G. Febbo, Ivo Shterev, Deanna L. Kroetz, Paula N. Friedman, John F. Mahoney, Michael A. Carducci, Michael J. Kelley, Yusuke Nakamura, Michiaki Kubo, Susan G. Dorsey, M. Eileen Dolan, Michael J. Morris, Mark J. Ratain, Howard L. McLeod
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (19): 4890–4900.
https://doi.org/10.1158/1078-0432.CCR-15-2823
Published: 02 October 2016
View articletitled, Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy
Open the PDF for Pharmacogenetic Discovery in CALGB (Alliance) 90401 and Mechanistic Validation of a VAC14 Polymorphism that Increases Risk of Docetaxel-Induced Neuropathy in another window
Includes: Supplementary data
Journal Articles

Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility

Daniel L. Hertz, James M. Rae
Journal: Clinical Cancer Research
Clin Cancer Res (2016) 22 (13): 3121–3123.
https://doi.org/10.1158/1078-0432.CCR-16-0370
Published: 30 June 2016
View articletitled, Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility
Open the PDF for Individualized Tamoxifen Dose Escalation: Confirmation of Feasibility, Question of Utility in another window
Journal Articles

Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology

Daniel L. Hertz, Howard L. McLeod
Journal: Clinical Cancer Research
Clin Cancer Res (2014) 20 (10): 2530–2540.
https://doi.org/10.1158/1078-0432.CCR-13-2780
Published: 14 May 2014
View articletitled, Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology
Open the PDF for Using Pharmacogene Polymorphism Panels to Detect Germline Pharmacodynamic Markers in Oncology in another window
Journal Articles

Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity

Sarah McWhinney-Glass, Stacey J. Winham, Daniel L. Hertz, Jane Yen Revollo, Jim Paul, Yijing He, Robert Brown, Alison A. Motsinger-Reif, Howard L. McLeod, For the Scottish Gynaecological Clinical Trials Group
Journal: Clinical Cancer Research
Clin Cancer Res (2013) 19 (20): 5769–5776.
https://doi.org/10.1158/1078-0432.CCR-13-0774
Published: 14 October 2013
View articletitled, Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity
Open the PDF for Cumulative Genetic Risk Predicts Platinum/Taxane-Induced Neurotoxicity in another window
Includes: Supplementary data